证券代码：002332 证券简称：仙琚制药 | --- | --- | --- | --- | --- | --- | |-------------------------------|------------------|------------------------------------------------------------------------------------|----------------------|----------------------------------|--------------------| | 投资者关系活动 \n类别 \n | □现场参观 | 特定对象调研现场会议 □分析师会议 \n媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n | | 其他电话会议 | 编号： 2022-009 | | 参与单位名称及 | 浙商证券 | 华创证券 | 中泰证券 | 广发证券 | 兴证医药 | | 人员姓名 | 永赢基金 | 天弘基金 | 翎展基金 | 大家资管 | 发展资产 | | | 国泰君安 | 东吴证券 | 源乘投资 | 国新证券 | 照友投资 | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,224,968,165.51, representing a year-on-year increase of 4.34%[9] - The net profit attributable to shareholders for the same period was ¥198,120,672.95, up 6.98% compared to the previous year[9] - The net profit after deducting non-recurring gains and losses was ¥188,329,142.28, reflecting a 5.95% increase year-on-year[9] - The company's basic earnings per share for Q3 2022 was ¥0.2003, an increase of 6.99% year-on-year[9] - Total operating revenue for the current period reached ¥3,452,994,013.86, an increase from ¥3,317,191,595.25 in the previous period, representing a growth of approximately 4.1%[30] - Operating profit for the current period was ¥658,236,093.00, compared to ¥558,228,356.10 in the previous period, indicating an increase of about 17.9%[33] - Net profit attributable to shareholders of the parent company was ¥529,212,330.11, up from ¥459,227,911.54 in the previous period, reflecting a growth of approximately 15.2%[36] - The total comprehensive income for the current period was ¥508,762,429.65, compared to ¥425,629,559.55 in the previous period, marking an increase of around 19.5%[36] - Basic and diluted earnings per share for the current period were both ¥0.5350, up from ¥0.4642 in the previous period, reflecting an increase of approximately 15.3%[36] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥6,717,131,761.80, showing a slight decrease of 0.09% from the end of the previous year[9] - The equity attributable to shareholders increased to ¥5,186,090,053.98, marking a growth of 7.39% compared to the end of the previous year[9] - As of September 30, 2022, the total current assets amounted to approximately CNY 3.50 billion, a slight decrease from CNY 3.55 billion at the beginning of the year, representing a decline of about 1.5%[24] - Total assets as of September 30, 2022, were CNY 6.72 billion, slightly down from CNY 6.73 billion at the beginning of the year, a decrease of about 0.1%[26] - Total liabilities decreased to CNY 1.48 billion from CNY 1.78 billion, representing a reduction of approximately 16.9%[26] - The company's fixed assets were valued at CNY 1.44 billion, down from CNY 1.62 billion, indicating a decrease of about 10.7%[26] - The company reported a total equity of CNY 5.24 billion, which remained stable compared to the previous period[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥366,266,769.53, which decreased by 25.14% year-on-year[9] - Cash flow from operating activities generated a net amount of ¥366,266,769.53, down from ¥489,272,169.41 in the previous period, a decrease of about 25.1%[37] - Investment cash outflow totaled $427,545,973.52, an increase from $176,802,076.94 in the previous period[40] - Net cash flow from investment activities was $29,341,038.61, recovering from a negative $137,418,121.03 last year[40] - Financing cash inflow amounted to $179,110,211.79, down from $335,680,641.75 in the previous period[40] - Cash outflow from financing activities was $647,520,967.79, slightly decreased from $661,714,463.78 last year[40] - Net cash flow from financing activities was -$468,410,756.00, worsening from -$326,033,822.03 in the previous period[40] - The net decrease in cash and cash equivalents was -$55,104,094.26, contrasting with an increase of $14,755,885.90 in the previous period[40] - The ending balance of cash and cash equivalents was $1,080,090,603.11, down from $1,213,586,617.63 last year[40] Shareholder Information - There were no significant changes in the top ten shareholders' equity structure, with the largest shareholder holding 21.55% of the shares[21] Research and Development - Research and development expenses for the current period were ¥150,824,651.11, slightly decreased from ¥156,896,426.83 in the previous period, a reduction of approximately 3.9%[30] Market Strategy - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[28] Other Financial Metrics - The weighted average return on net assets was 3.88%, a decrease of 0.10% compared to the previous year[9] - The company experienced a 113.29% increase in prepayments compared to the beginning of the year, amounting to an increase of ¥25,518,000[14] - The company reported a decrease in other comprehensive income after tax of ¥-23,969,658.40 compared to ¥-35,415,822.61 in the previous period, indicating an improvement[36]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 2,228,025,848.35, representing a 3.96% increase compared to CNY 2,143,203,846.80 in the same period last year[29]. - The net profit attributable to shareholders of the listed company reached CNY 331,091,657.16, marking a 20.82% increase from CNY 274,040,318.92 year-on-year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 310,097,346.49, up 14.62% from CNY 270,554,642.01 in the previous year[29]. - The net cash flow from operating activities was CNY 128,631,190.98, a decrease of 45.05% compared to CNY 234,107,076.76 in the same period last year[29]. - Basic earnings per share increased to CNY 0.33, up 17.86% from CNY 0.28 in the previous year[29]. - Total assets at the end of the reporting period were CNY 6,635,403,263.70, a decrease of 1.31% from CNY 6,723,208,000.32 at the end of the previous year[29]. - The net assets attributable to shareholders of the listed company were CNY 4,989,079,652.21, reflecting a 3.31% increase from CNY 4,829,228,112.17 at the end of the previous year[29]. - The weighted average return on net assets was 6.71%, an increase of 0.65% compared to 6.06% in the previous year[29]. - The total profit amounted to 404.22 million yuan, with a year-on-year increase of 20.71%[51]. - The sales revenue from formulations was 1.353 billion yuan, showing a growth of 16% year-on-year[51]. - The sales revenue from raw materials and intermediates was 853 million yuan, reflecting an 11% decline year-on-year[51]. Business Operations - The company operates in the pharmaceutical manufacturing industry, which is a strategic emerging industry in China, benefiting from a comprehensive medical security network[39]. - The main business includes the research, production, and sales of steroid raw materials and formulations, with key products in corticosteroids, sex hormones, anesthetics, and respiratory drugs[40]. - The company has established stable business relationships with over 100 domestic steroid drug manufacturers, maintaining a stable market share in the domestic market[44]. - The company has expanded its international sales network, establishing connections with over 40 foreign pharmaceutical companies across more than 30 countries[44]. - The company faced challenges from rising raw material costs and the impact of centralized drug procurement but achieved steady growth through strategic adjustments[43]. - The company focuses on optimizing resource allocation and integrating subsidiaries to enhance operational efficiency[43]. - The company has developed a mature marketing model, combining online and offline sales channels to ensure sustainable growth[44]. - The company emphasizes internal management and continuous learning to improve operational standards and address gaps[43]. - The company is committed to deepening research and development in raw materials to enrich its product line and enhance industry chain benefits[43]. Research and Development - The company has a strong R&D pipeline and has formed a technical architecture system with international high-end research institutions[48]. - The company focuses on an integrated business model of raw materials and formulations, which enhances its competitive advantage in the steroid hormone sector[49]. - The company is actively expanding its CDMO (Contract Development and Manufacturing Organization) services and increasing investment in enzyme engineering research[55]. - The company has made significant progress in its high-end formulation construction project, which includes a production line with an annual capacity of 5 million bottles for pulmonary drug delivery[59]. - The company has received approval for new generic products, including Methylprednisolone tablets and Sugammadex sodium raw materials and formulations[55]. - The company has committed to substantial annual investments in R&D and consistency evaluations for generic drugs to mitigate risks associated with regulatory changes and market competition[107]. Environmental and Social Responsibility - The company has implemented a robust environmental protection strategy, achieving ISO14001 certification and being recognized as a "Green Factory" by the Ministry of Industry and Information Technology[137]. - Environmental compliance is a priority, with all pollutant emissions meeting regulatory standards, although future regulations may impose higher costs[109]. - The company reported a total pollutant discharge of 18.03 tons of COD and 0.83 tons of ammonia nitrogen, all within the permitted limits[122]. - The company has established a comprehensive quality assurance system, adhering to international GMP standards, ensuring product safety and quality throughout the production process[135]. - The company actively participates in social responsibility initiatives, including the establishment of the Sunshine Angel Foundation, which focuses on reproductive health and AIDS prevention[138]. - The company has introduced employee welfare measures such as an "enterprise annuity plan" and "major illness medical insurance" to enhance employee benefits[133]. - The company emphasizes employee rights protection, providing a good working environment and signing labor contracts with all employees[131]. - The company conducts regular health check-ups for employees and organizes safety training to enhance awareness and skills related to occupational health and safety[132]. Financial Management and Investments - The company has a total approved external guarantee limit of 26,000,000 CNY, with an actual external guarantee balance of 7,000,000 CNY at the end of the reporting period[165]. - The company has invested 50,000 million in bank financial products, with the entire amount still outstanding and no overdue amounts reported[178]. - The company has no overdue or uncollectible financial management amounts, indicating strong financial management practices[178]. - The company has not engaged in any securities or derivative investments during the reporting period[79][80]. - The company has not experienced any major changes in project feasibility or significant delays in planned progress or expected benefits[88]. - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[90]. - The company has not made any guarantees that violate regulations during the reporting period[148]. Risks and Challenges - The management has highlighted potential risks and corresponding measures in the future operations[7]. - The company faces risks from changes in industry policies and drug price reductions, which could impact production costs and profitability[106]. - Quality control risks are heightened due to new regulations and standards in drug management and production, necessitating improved operational quality[106]. - The company faces significant R&D risks due to the lengthy and costly drug development process, which may lead to financial losses if market demand does not align with development progress[107]. - The company has experienced rising comprehensive management costs, including increased fixed asset depreciation and financial costs, which may impact profitability[109]. - Talent acquisition and retention are critical as the company expands, necessitating a focus on developing a skilled workforce to meet strategic goals[109].

Revenue and Profitability - The company's revenue for Q1 2022 was ¥1,049,027,960.34, representing a 4.76% increase compared to ¥1,001,363,720.40 in the same period last year[3] - Net profit attributable to shareholders was ¥127,713,332.35, up 15.47% from ¥110,602,233.70 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥126,262,345.28, reflecting a 16.26% increase from ¥108,605,653.74 in the previous year[3] - Total operating revenue for the current period reached ¥1,049,027,960.34, an increase of 4.8% compared to ¥1,001,363,720.40 in the previous period[21] - Net profit for the current period was ¥122,094,681.17, compared to ¥112,589,627.22 in the previous period, representing an increase of 8.9%[24] - The net profit attributable to the parent company was ¥127,713,332.35, up from ¥110,602,233.70, marking a growth of 15.4%[27] - The total comprehensive income for the current period was ¥108,595,308.92, compared to ¥93,002,355.96 in the previous period, reflecting an increase of 16.8%[27] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 90.81%, amounting to ¥5,935,810.00 compared to ¥64,571,088.88 in the same period last year[3] - The net cash flow from operating activities was 5,935,810.00, a significant decrease from 64,571,088.88 in the previous period, indicating a decline in operational efficiency[30] - Cash inflow from operating activities totaled 926,986,324.31, while cash outflow was 921,050,514.31, resulting in a narrow margin of cash generation[30] - The net cash flow from investing activities was -63,740,310.49, compared to -15,785,339.55 previously, reflecting increased investment expenditures[33] - Cash inflow from financing activities was 110,800,000.00, down from 245,653,380.25, indicating reduced capital raising efforts[33] - The net cash flow from financing activities improved to 34,664,410.03 from -12,153,374.42, suggesting better management of financing costs[33] - The ending balance of cash and cash equivalents was 1,108,175,110.49, down from 1,242,588,429.15, showing a decrease in liquidity[33] - The company received 1,804,013.95 in tax refunds, a decrease from 8,056,092.18, indicating a potential decline in tax efficiency[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,835,092,522.06, a 1.66% increase from ¥6,723,208,000.32 at the end of the previous year[3] - Shareholders' equity attributable to the parent company increased by 2.37% to ¥4,943,442,072.27 from ¥4,829,228,112.17 at the end of the previous year[3] - The total liabilities amounted to ¥1,781,605,150.92, slightly up from ¥1,778,315,938.10, indicating a marginal increase of 0.1%[19] - Total equity increased to ¥5,053,487,371.14 from ¥4,944,892,062.22, reflecting a growth of 2.2%[19] - Total current liabilities amounted to approximately CNY 1.40 billion, up from CNY 1.39 billion, indicating a growth of about 0.97%[16] Investments and Expenses - Research and development expenses for the current period were ¥57,373,399.37, compared to ¥51,854,252.28 in the previous period, showing an increase of 10.0%[24] - The company reported a notable increase in accounts payable, which stood at approximately CNY 299.57 million, down from CNY 310.60 million, a decrease of about 3.34%[16] - Cash outflow for investment activities rose significantly to 64,846,177.89 from 15,802,784.22, indicating aggressive investment strategies[33] - The company reported a cash inflow of 831,250.00 from other investment activities, highlighting additional revenue streams[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 47,370[8]

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the year 2021, representing a year-on-year growth of 15%[5]. - The net profit attributable to shareholders was 250 million CNY, an increase of 20% compared to the previous year[5]. - The company's operating revenue for 2021 was ¥4,337,150,964.75, representing a 7.92% increase from ¥4,018,872,772.40 in 2020[28]. - Net profit attributable to shareholders for 2021 was ¥615,942,771.05, a 22.09% increase compared to ¥504,509,427.41 in 2020[28]. - The net profit after deducting non-recurring gains and losses was ¥581,194,088.37, reflecting a 26.46% increase from ¥459,591,327.12 in 2020[28]. - The company achieved operating revenue of CNY 4.34 billion, a year-on-year increase of 7.92%[59]. - Net profit attributable to shareholders reached CNY 615.94 million, up 22.09% year-on-year, with earnings per share of CNY 0.62, reflecting a 12.73% increase[51]. - The company reported a total revenue of 14,691,834,000, with a net profit of 1,520,640,000 for the fiscal year[186]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[199]. - The net profit for the year was 300 million RMB, an increase of 20% compared to the previous year[199]. User Engagement and Market Expansion - The company highlighted a significant increase in user data, with a 30% rise in active users of its pharmaceutical products[5]. - User data showed a 25% increase in active users, reaching 2 million by the end of 2021[199]. - Future outlook includes a projected revenue growth of 10% for 2022, driven by new product launches and market expansion strategies[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[199]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2023[158]. Research and Development - The company is investing 200 million CNY in R&D for new drug development in the next fiscal year[5]. - The company has received five national invention patents during the reporting period, indicating strong R&D capabilities[54]. - The company is developing multiple new products in gynecology and anesthesia, aiming to expand its product lines[88]. - The company is committed to accelerating product research and development, focusing on key products such as progesterone gel and mometasone nasal spray, while also pursuing new formulation breakthroughs[140]. - The company is investing 100 million RMB in R&D for new technologies in the pharmaceutical sector[199]. Operational Efficiency and Cost Control - The company has optimized its production system and applied new technologies to improve operational efficiency and market responsiveness[47]. - The company has optimized its internal management and cost control, resulting in significant operational efficiency improvements[51]. - The company is implementing lean production management to improve operational efficiency and transition from a "cost center" to a "profit center" approach[140]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[199]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost control measures[158]. Strategic Initiatives and Acquisitions - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[5]. - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to add 50 million RMB in annual revenue[158]. - The company plans to enhance its internationalization of chemical raw materials, using Newchem as a benchmark for global steroid hormone industry chain integration[135]. - The company aims to leverage its existing market presence to explore potential mergers and acquisitions in the pharmaceutical sector[187]. Risk Management and Compliance - The management identified risks including regulatory changes and rising operational costs, which could impact future performance[5]. - The company aims to improve its quality control processes to mitigate risks associated with product recalls and compliance issues[5]. - New regulations in drug management and quality control require the company to improve its operational quality and ensure compliance throughout the drug lifecycle[145]. - The company recognizes the risk of talent shortages as it expands and integrates acquisitions, emphasizing the need for skilled professionals[147]. Corporate Governance and Investor Relations - The company actively respects and protects the rights of stakeholders, promoting balanced interests among shareholders, employees, and society[170]. - The company has established a robust information disclosure system, ensuring timely and accurate communication with investors[171]. - The company has plans for market expansion and new product development, focusing on innovative pharmaceutical solutions[187]. - The company is committed to enhancing corporate governance and investor relations, ensuring timely and accurate information disclosure to protect investor rights[141].

证券代码：002332 证券简称：仙琚制药 公告编号：2022-019 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2022年4月21日发布了《2021 年年度报告》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接 待日活动，现将有关事项公告如下： 一、活动时间 2022年5月12日（星期四）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2022年5月10-11日（上午8:30-11:00，下午14:00-16:00）与公 司董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和 安排。 联系人：沈旭红 高晶 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长、总经理张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生（如 有特殊情况，参与人员会有调整）。 五、注意事项 1、来访个人投资者请携带个 ...

Financial Performance - The company's revenue for Q3 2021 was ¥1,173,987,748.45, representing a 0.96% increase year-over-year[3] - Net profit attributable to shareholders was ¥185,187,592.62, up 20.93% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses reached ¥177,760,359.94, reflecting a 21.12% increase year-over-year[3] - Total operating revenue for the current period reached ¥3,317,191,595.25, an increase of 13.1% compared to ¥2,933,659,236.31 in the previous period[24] - Operating profit for the current period was ¥558,228,356.10, up from ¥470,527,145.59, reflecting a growth of 18.6%[24] - Net profit attributable to the parent company was ¥459,227,911.54, compared to ¥358,457,332.81 in the previous period, marking a 28.0% increase[27] - The total comprehensive income for the current period was ¥425,629,559.55, compared to ¥381,646,475.88, an increase of 11.5%[27] - Basic earnings per share for the current period was ¥0.4642, up from ¥0.39 in the previous period, an increase of 18.0%[27] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,995,904,196.50, a 2.31% increase from the end of the previous year[3] - The equity attributable to shareholders increased to ¥4,720,174,142.12, marking a 6.19% rise compared to the end of last year[3] - Total liabilities decreased to ¥2,162,369,113.40 from ¥2,255,881,487.04, a reduction of 4.1%[24] - The company’s total liabilities increased by 55.61% for non-current liabilities due within one year, amounting to an increase of ¥162,987,100[6] - Total cash and cash equivalents at the end of the period amounted to 1,213,586,617.63, up from 960,115,539.77 in the previous period, representing an increase of approximately 26.38%[35] Cash Flow - Cash flow from operating activities for the year-to-date was ¥489,272,169.41, showing a 3.69% increase[3] - Cash flow from operating activities was ¥2,883,823,085.02, compared to ¥2,523,286,342.21, indicating a growth of 14.3%[29] - The net cash flow from operating activities was 489,272,169.41, an increase from 471,861,338.07 in the previous period, reflecting a growth of approximately 0.87%[32] - The net cash flow from financing activities was -326,033,822.03, worsening from -114,778,625.43 in the previous period, showing a significant decline[35] Investments and Expenses - The company reported a significant increase in investment income of 224.93%, amounting to an increase of ¥861.57 million[6] - The company experienced a 59.61% decrease in financial expenses, down by ¥26,379,100[6] - Research and development expenses increased to ¥156,896,426.83, up from ¥133,012,662.97, representing an increase of 18.0%[24] - The company reported a decrease in financial expenses to ¥17,870,828.20 from ¥44,249,974.84, a reduction of 59.7%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period was 37,000[10] - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holds 21.55% of shares, totaling 213,221,808 shares[10] Other Financial Metrics - The company reported a decrease in goodwill from ¥619,766,791.91 to ¥581,128,869.67[16] - Cash paid for purchasing goods and services was 671,448,016.59, an increase from 605,876,000.95, indicating a rise of approximately 10.5%[32] - Cash paid for employee compensation was 485,054,008.61, compared to 433,743,398.36 in the previous period, marking an increase of about 11.8%[32] - Cash outflow from investment activities totaled 176,802,076.94, up from 126,709,134.42, indicating an increase of approximately 39.5%[32] - The company reported cash received from other operating activities of 100,327,144.54, down from 173,327,482.32, reflecting a decrease of about 42.2%[32]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 2,143,203,846.80, representing a 21.03% increase compared to CNY 1,770,808,591.63 in the same period last year[29]. - The net profit attributable to shareholders of the listed company reached CNY 274,040,318.92, up 33.47% from CNY 205,317,915.18 in the previous year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 270,554,642.01, reflecting a 37.11% increase from CNY 197,328,956.79 year-on-year[29]. - The basic earnings per share increased to CNY 0.28, a rise of 27.27% compared to CNY 0.22 in the same period last year[29]. - The total assets at the end of the reporting period were CNY 6,887,522,958.74, showing a 0.72% increase from CNY 6,838,231,066.49 at the end of the previous year[29]. - The net assets attributable to shareholders of the listed company increased by 2.35% to CNY 4,549,287,414.08 from CNY 4,444,931,882.40 at the end of the previous year[29]. - The net cash flow from operating activities was CNY 234,107,076.76, which is a decrease of 4.14% compared to CNY 244,208,628.76 in the same period last year[29]. - The weighted average return on net assets was 6.06%, down from 6.81% in the previous year, indicating a decrease of 0.75%[29]. Revenue Breakdown - Sales revenue from formulations was 1.162 billion yuan, a 31% increase, with self-operated product sales reaching 1.134 billion yuan, up 38%[40]. - The sales revenue of raw materials and intermediates was 964 million yuan, a 9.5% increase, with self-operated raw material sales at 595 million yuan, up 16%[40]. - Domestic sales accounted for ¥1,527,052,896.59, which is 71.25% of total revenue, showing a growth of 29.09% compared to the previous year[69]. - The revenue from anesthetics and muscle relaxants surged by 68.86% to ¥393,975,393.22, contributing 18.38% to total revenue[69]. Research and Development - Research and development expenses increased by 30.48% to CNY 99,242,121.29, up from CNY 76,058,999.29 in the previous year[66]. - The company is actively advancing product research and development, with several new drug applications and consistency evaluations in progress, including Dexamethasone sodium phosphate injection[51]. - The company has successfully passed consistency evaluations for several products, including Finasteride tablets and Mifepristone tablets, enhancing its product portfolio[51]. - The company has submitted applications for 22 consistency evaluation products, with 8 submitted and 4 passed, and 18 new generic products, with 5 submitted[54]. Market Position and Strategy - The company focuses on the steroid drug sector, emphasizing the integration of raw materials and formulations to enhance competitiveness[45]. - The company is actively expanding its international market presence, with steady progress in developing raw material customers[45]. - The company is positioned in a stable competitive landscape within the steroid hormone industry, maintaining a strong market share in the first tier of the industry[49]. - The steroid drug industry in China accounts for approximately one-third of the global production of steroid raw materials, indicating a significant production capacity[47]. Risks and Challenges - The company has identified several risks including industry policy changes, drug price reduction risks, and R&D risks, which are detailed in the management discussion section[6]. - The company faces risks from industry policy changes and potential drug price reductions due to stricter regulations and reforms in the healthcare system[97]. - Quality control risks are heightened due to new regulations and standards impacting the entire lifecycle of drug development and production[98]. - R&D risks are present due to high investment and long cycles associated with new drug development, necessitating a focus on core therapeutic areas[98]. - Environmental risks are increasing due to stricter pollution control regulations, prompting the company to enhance its environmental protection measures[99]. Environmental Responsibility - The company reported a total COD discharge of 1.01 tons and ammonia nitrogen discharge of 0.27 tons from its Jiangnan plant, adhering to environmental standards[110]. - The company has a pollution prevention facility in operation, ensuring compliance with environmental regulations[113]. - The company achieved a stable operation rate of over 99% for its environmental protection facilities during the reporting period[114]. - The company has established a complete internal control system and an investor interaction platform to ensure fair treatment of all shareholders[120]. Shareholder Information - The total number of shareholders at the end of the reporting period was 35,247, with a significant shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holding 21.55% of shares, totaling 213,221,808 shares[190]. - The total number of shares is 989,204,866, with 97.30% being unrestricted shares[182]. - The company has a total of 4,379,562 shares subscribed by Huatai Asset Management Co., Ltd. and 4,014,598 shares by China Merchants Fund Management Co., Ltd., both of which have also completed their lock-up commitments[135][138]. - The report indicates that the company has not experienced any significant changes in shareholder structure during the reporting period[190].

证券代码：002332 证券简称：仙琚制药 公告编号：2021-026 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2021年4月28日发布了《2020 年年度报告》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接 待日活动，现将有关事项公告如下： 一、活动时间 2021年5月19日（星期三）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2021年5月17-18日（上午8:30-11:00，下午14:00-16:00）与公 司董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和 安排。 联系人：沈旭红 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长兼总经理张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生（如 有特殊情况，参与人员会有调整）。 五、注意事项 1、来访个人投资者请携带个人身份 ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2020, representing a year-on-year growth of 15%[7]. - The net profit attributable to shareholders was 250 million RMB, an increase of 20% compared to the previous year[7]. - The company's operating revenue for 2020 was ¥4,018,872,772.40, an increase of 8.37% compared to ¥3,708,545,530.97 in 2019[27]. - Net profit attributable to shareholders for 2020 was ¥504,509,427.41, representing a growth of 22.94% from ¥410,368,585.97 in 2019[27]. - The total profit reached 621.25 million yuan, up 17.82% year-on-year, while net profit attributable to shareholders was 504.51 million yuan, reflecting a 22.94% increase[65]. - The company achieved a revenue of 4,018.87 million CNY, representing a year-on-year growth of 8.37%[44]. - The net cash flow from operating activities increased by 51.83% to ¥789,233,376.74 from ¥519,805,113.67 in 2019[27]. - The company reported a total sales volume of 400,196.45 million yuan in 2020, an increase of 8.27% from 2019[82]. Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares, based on a total share capital of 989,204,866 shares as of December 31, 2020[7]. - In 2020, the company distributed cash dividends totaling ¥148,380,729.90, which represents 29.41% of the net profit attributable to shareholders of the listed company[164]. - The net profit attributable to shareholders for 2020 was ¥504,509,427.41, with a profit distribution base of 989,204,866 shares, resulting in a cash dividend of ¥1.5 per 10 shares[167]. - The total distributable profit for the year was ¥931,501,460.58, with cash dividends accounting for 100% of the profit distribution[167]. - The company executed a cash dividend of 1 CNY per 10 shares for the 2019 fiscal year, amounting to approximately 91.62 million CNY[163]. - The company issued a cash dividend of 0.65 CNY per 10 shares for the 2018 fiscal year, totaling approximately 59.55 million CNY[163]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its R&D capabilities to drive future growth[7]. - New product launches are expected to contribute significantly to revenue in the upcoming fiscal year, with a target of introducing at least 5 new drugs[7]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[7]. - The company aims to achieve a revenue growth target of 20% for the next fiscal year, driven by new product introductions and market expansion strategies[7]. - The company is actively expanding into international markets, enhancing its market share in the global steroid industry[44]. - The company aims to enhance market share in the raw material drug sales by coordinating various departments and responding quickly to market demands, focusing on high-end market expansion in Latin America, the Middle East, and Russia[142]. Research and Development - The company is investing heavily in technology development, with a budget allocation of 100 million RMB for R&D in 2021[7]. - The company received 7 national invention patents during the reporting period, bringing the total to 42 authorized patents, enhancing its R&D capabilities[58]. - Research and development investment amounted to ¥208,385,907.97 in 2020, representing a 1.89% increase from ¥204,521,925.83 in 2019[101]. - The number of R&D personnel increased to 448, a 4.19% rise from 430 in the previous year[101]. - Continuous improvement of R&D capabilities is emphasized, with a focus on consistency evaluation and innovative R&D projects, aiming to establish a stable performance in the production line and develop a steroid drug API platform[143]. Risk Management - The company has identified key risks including industry policy changes, drug price reductions, and R&D risks, which may impact future performance[7]. - The company is addressing risks related to industry policy changes and drug price reductions by closely monitoring industry trends and enhancing innovative product development[149]. - The company faces quality control risks due to new regulations and standards, necessitating improved coordination among research, production, and quality departments[150]. - The company recognizes the risk of talent shortages as it expands and integrates acquisitions, emphasizing the need for skilled professionals with international perspectives[151]. Operational Efficiency - The company has a strong emphasis on internal management and cost control, resulting in significant operational efficiency improvements[44]. - The company is committed to compliance production and comprehensive cost control, establishing a new responsibility assessment system to enhance operational efficiency and production capacity[144]. - Quality management systems are being enhanced to meet international standards, with ongoing efforts in the registration of international raw material drug varieties and compliance with GMP standards[145]. - The implementation of an integrated management system through the Kingdee ERP project aims to optimize business processes and improve operational efficiency across various departments[146]. Subsidiaries and Investments - The company established two new subsidiaries, Jiaxing Pharmaceutical Company and Hangzhou Technology Innovation Company, with an investment of 3.5 million yuan each, acquiring a 70% stake in both[192]. - The subsidiary Taizhou Xianju Pharmaceutical Co., Ltd. reported a net profit of ¥76,404,900, contributing over 10% to the company's net profit[127]. - The company has invested in several overseas subsidiaries, with total foreign equity assets amounting to CNY 30.99 million for Newchem and CNY 28.23 million for Effechem, contributing positively to revenue[53]. Compliance and Governance - The company has committed to strict adherence to share lock-up agreements for its major shareholders following the non-public issuance of A-shares[171]. - The company has a commitment from its actual controller and major shareholders to fulfill their obligations during the reporting period[168]. - The company has not faced any major litigation or arbitration matters during the reporting period[198]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 20 years, with an audit fee of 1.85 million yuan for the current period[193].